跳至主要内容
临床试验/CTRI/2025/02/080991
CTRI/2025/02/080991尚未招募3 期

Efficacy of Virechana Karma and Lekhana Basti along with Pathadi Yoga Ghanavati and Phalatrikadi Kwatha in ovulation induction in obese polycystic ovarian syndrome: open labelled randomized controlled clinical trial

Institute of Teaching and Research in Ayurveda Jamnagar Gujarat1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年3月11日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
20
试验地点
1
主要终点
It is expected that treatment protocol will help in growth of dominant follicle, ovulation, reduction of ovarian volume as well as menstrual regulation,

研究概览

简要总结

‘‘EFFICACY OF VIRECHANA KARMA AND LEKHANA BASTI ALONG WITH PATHADI YOGA GHANAVATI AND PHALATRIKADI KWATHA IN OVULATION INDUCTION IN OBESE POLYCYSTIC OVARIAN SYNDROME: OPEN LABELLED RANDOMISED CONTROLLED CLINICAL TRIAL’’ Introduction: Polycystic Ovarian Syndrome [PCOS] is the most common endocrine and metabolic disorder in a woman of reproductive age. Majority of cases with PCOS are obese/overweight in the population. Obesity or overweight affects between 38 and 88% of women with PCOS. It is a complex syndrome showing the clinical features of an endocrine/metabolic disorder, including hyperinsulinemia and hyperandrogenism. Clinically it is characterized by menstrual abnormalities, hirsutism, acne, obesity, insulin resistance. It is also the most frequent condition for anovulatory cycles leading to infertility. In Kashyapa Samhita, Lakshanas of Vrithapushpa (anovulation) has been mentioned in the context of Pushpaghni Jataharini. Rationality For the Selection of The Topic: Ashtanga Sangraha has clearly mentioned role of Virechana Karma in Granthi Chikitsa. Granthi is a Bahu Dosha Janya Vikara, for Prabhuta Dosha in the body Samshodhana therapy is indicated. In Obese PCOS Vata-kapha predominance is there & there is Aavarana due to kapha Dosha. As Lekhana Basti possesses Lekhana, Pachana, Ushna and Tikshna properties. It offers Vatakapha Shamaka, Srotoshodhaka and Amapachana actions. Lekhana Basti lower LH level and normalize the FSH level to encourage the growth and development of follicles in PCOS patient. Pathadi Choorna is primarily mentioned in treatment of Vata-Kaphaja type of Artava Dushti in Sushruta Samhita Sharira Sthana,which have shown encouraging results in clinical features of PCOS. Arogyavardhini Rasa possesses Deepana-Pachana, Tridoshahara, Rasayana, Vrushya, Medovinashini, and Lekhana properties. It is indicated in Rogadhikara Jwara, Prameha, and Kushtha and is useful in metabolic disorders. As acharya Charaka has mentioned this Kwatha for Prameha, so considering the Insulin resistance condition in PCOS patient, this drug will be beneficial. Aims and Objectives Aim:

  1. To evaluate the efficacy of Virechana Karma and Lekhana Basti along with Pathadi Yoga Ghanavati and Phalatrikadi Kwatha in ovulation induction in obese polycystic ovarian syndrome and compare it with standard drug Letrozole and Metformin. Objectives: 1.To assess the effect of Virechana Karma and Lekhana Basti along with Pathadi Yoga Ghanavati and Phalatrikadi Kwatha in follicular development and ovulation in obese polycystic ovarian syndrome. 2.To assess the effect of Virechana Karma and Lekhana Basti along with Pathadi Yoga Ghanavati and Phalatrikadi Kwatha on ovarian morphology, obesity and regulation in menstrual pattern. Materials And Methods: Diagnosed 20 patients of obese PCOS, fulfilling the Rotterdam criteria (2018) from the O.P.D. of P.T.S.R. Dept. of ITRA, Jamnagar will be screened with transvaginal sonography for anovulation for two consecutive cycles and patients having anovulatory cycles will be registered for clinical trial. Results And Discussion: Data generated during the above study will be presented in a systemic methodical manner as shall be analysed and the section where the important points of the Conceptual study, Clinical study, Pharmacological study will be discussed. Follow up periods: Patients will be advised to visit the hospital every 15 days during the treatment period & every 15 days for 1 Cycles after the treatment as follow-up. Side Effects: These drugs have no known unwanted effects. It is possible that it may also cause some problems that we are not aware of. Adverse Drug Reaction if any observed will be reported to the Pharmacovigilance cell of I.T.R.A., Jamnagar

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • Patients with BMI more than 30 kg/m2 Patients with any 3 or more clinical features of PCOD like- Amenorrhea or Oligomenorrhoea Anovulation Infertility (Due to anovulation) Acne Hirsutism (Ferryman-Gallwey scale) Acanthosis nigricans.
  • Confirmation of Polycystic Ovary along with anovulatory cycles in USG finding.
  • Patient eligible for Virechana Karma and Lekhana Basti.

排除标准

  • Patient with infectious diseases of reproductive tract like tuberculosis, sexually transmitted diseases.
  • Organic lesions of reproductive tract like tuberculosis, carcinoma and congenital deformities.
  • Patients with history of cardiac diseases, Chronic liver disease, Uncontrolled Diabetes more than 160 mg/dl- fasting blood sugar and Hypertension Systolic blood pressure more than 160 and Diastolic more than 100mmhg, Tuberculosis Patient with Hepatitis C, Hepatitis B, Hyperprolactinemia, Hypothyroidism.
  • Patient not eligible for Virechana Karma and Lekhana Basti.

结局指标

主要结局

It is expected that treatment protocol will help in growth of dominant follicle, ovulation, reduction of ovarian volume as well as menstrual regulation,

时间窗: During treatment period of 4 month

Reduction in body weight, Waist hip ratio, Insulin Resistance and Hirsutism

时间窗: During treatment period of 4 month

次要结局

  • Treatment protocol will help in conception(During treatment period of 4 month)

研究者

发起方
Institute of Teaching and Research in Ayurveda Jamnagar Gujarat
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Nidhi Bipinkumar Patel

Institute of Teaching and Research in Ayurveda Jamnagar

研究点 (1)

Loading locations...

相似试验

ayurvedic management of Obese PCOS | 临床试验